{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:44:28Z","timestamp":1782992668449,"version":"3.54.5"},"reference-count":26,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biomarkers are desirable to characterize individual tumors and to personalize multimodal treatment in locally advanced rectal cancer patients. In this regard, monitoring of High Mobility Group Box 1 (HMGB1) protein in blood samples is of interest in radiotherapy as HMGB1 is a consensus marker for immunogenic cell death (ICD) during anticancer treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>Plasma levels of HMGB1 were monitored weekly during long-term neoadjuvant chemoradiotherapy in 19 patients with locally advanced rectal cancer. HMGB1 levels were correlated with outcome and tumor volumes in magnetic resonance imaging (MRI) pre-therapeutically as well as in week 2 and week 5 of treatment. Furthermore, the association with circulating cell-free tumor DNA (ctDNA) was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Higher pre-therapeutic levels of HMGB1 correlated positively with bigger initial MRI volumes and higher allele frequencies of ctDNA in the corresponding baseline blood sample. Courses of HMGB1 during treatment were variable and mostly undulating. Predominant ascent was observed in four patients who showed poor pathologic response. Declining levels in week 2 \/ 3 were associated with bigger percentage decrease of MRI tumor volume at the end of week 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HMGB1 seems to be associated mostly with tumor burden as indicated by correlation with MRI volumes and ctDNA levels, rather than ICD induction or side effects as previously reported. Changes during treatment might predict clinical disease course.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2026-0033","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:09:06Z","timestamp":1782468546000},"page":"294-300","source":"Crossref","is-referenced-by-count":0,"title":["Weekly measurement of HMGB1 during neoadjuvant chemoradiotherapy in rectal cancer patients: correlations with MRI response and ctDNA"],"prefix":"10.2478","volume":"60","author":[{"given":"Franziska","family":"Eckert","sequence":"first","affiliation":[{"name":"1 Department of Radiation Oncology, University Hospital T\u00fcbingen , T\u00fcbingen , Germany"},{"name":"2 Department of Radiation Oncology, Medical University Vienna, CCC Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlatko","family":"Potkrajcic","sequence":"additional","affiliation":[{"name":"1 Department of Radiation Oncology, University Hospital T\u00fcbingen , T\u00fcbingen , Germany"},{"name":"2 Department of Radiation Oncology, Medical University Vienna, CCC Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Clasen","sequence":"additional","affiliation":[{"name":"3 Department of Diagnostic and Interventional Radiology, District Hospital Reutlingen , Reutlingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elgin","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"1 Department of Radiation Oncology, University Hospital T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Taugner","sequence":"additional","affiliation":[{"name":"1 Department of Radiation Oncology, University Hospital T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Seibel-Kelemen","sequence":"additional","affiliation":[{"name":"4 Institute of Medical Genetics and Applied Genomics, University Hospital T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Schroeder","sequence":"additional","affiliation":[{"name":"4 Institute of Medical Genetics and Applied Genomics, University Hospital T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Niyazi","sequence":"additional","affiliation":[{"name":"1 Department of Radiation Oncology, University Hospital T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Clasen","sequence":"additional","affiliation":[{"name":"1 Department of Radiation Oncology, University Hospital T\u00fcbingen , T\u00fcbingen , Germany"},{"name":"5 RadioChirurgicum, CyberKnife S\u00fcdwest , G\u00f6ppingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"2026070211005179448_j_raon-2026-0033_ref_001","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. NCCN guidelines insights: Rectal cancer, Version 6.2020. J Natl Compr Canc Netw 2020; 18: 806-15. doi: 10.6004\/j\u0149ccn.2020.0032"},{"key":"2026070211005179448_j_raon-2026-0033_ref_002","doi-asserted-by":"crossref","unstructured":"Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012; 30: 1926-33. doi: 10.1200\/JCO.2011.40.1836","DOI":"10.1200\/JCO.2011.40.1836"},{"key":"2026070211005179448_j_raon-2026-0033_ref_003","doi-asserted-by":"crossref","unstructured":"Conroy T, Bosset JF, Etienne PL, Rio E, Francois E, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22: 702-15. doi: 10.1016\/S1470-2045(21)00079-6","DOI":"10.1016\/S1470-2045(21)00079-6"},{"key":"2026070211005179448_j_raon-2026-0033_ref_004","doi-asserted-by":"crossref","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22: 29-42. doi: 10.1016\/S1470-2045(20)30555-6","DOI":"10.1016\/S1470-2045(20)30555-6"},{"key":"2026070211005179448_j_raon-2026-0033_ref_005","doi-asserted-by":"crossref","unstructured":"Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 2022; 40: 2546-56. doi: 10.1200\/JCO.22.00032","DOI":"10.1200\/JCO.2022.40.16_suppl.3619"},{"key":"2026070211005179448_j_raon-2026-0033_ref_006","doi-asserted-by":"crossref","unstructured":"Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010; 11: 835-44. doi: 10.1016\/S1470-2045(10)70172-8","DOI":"10.1016\/S1470-2045(10)70172-8"},{"key":"2026070211005179448_j_raon-2026-0033_ref_007","doi-asserted-by":"crossref","unstructured":"Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003; 22: 5551-60. doi: 10.1093\/emboj\/cdg516","DOI":"10.1093\/emboj\/cdg516"},{"key":"2026070211005179448_j_raon-2026-0033_ref_008","doi-asserted-by":"crossref","unstructured":"Kwak MS, Kim HS, Lee B, Kim YH, Son M, Shin JS. Immunological significance of HMGB1 post-translational modification and redox biology. Front Immunol 2020; 11: 1189. doi: 10.1038\/s12276-022-00736-w","DOI":"10.3389\/fimmu.2020.01189"},{"key":"2026070211005179448_j_raon-2026-0033_ref_009","doi-asserted-by":"crossref","unstructured":"Chen R, Kang R, Tang D. The mechanism of HMGB1 secretion and release. Exp Mol Med 2022; 54: 91-102. doi: 10.1038\/s12276-022-00736-w","DOI":"10.1038\/s12276-022-00736-w"},{"key":"2026070211005179448_j_raon-2026-0033_ref_010","doi-asserted-by":"crossref","unstructured":"Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014; 3: e955691. doi: 10.4161\/21624011.2014.955691","DOI":"10.4161\/21624011.2014.955691"},{"key":"2026070211005179448_j_raon-2026-0033_ref_011","doi-asserted-by":"crossref","unstructured":"Liao Y, Liu S, Fu S, Wu J. HMGB1 in radiotherapy: a two headed signal regulating tumor radiosensitivity and immunity. Onco Targets Ther 2020; 13: 6859-71. doi: 10.2147\/OTT.S253772","DOI":"10.2147\/OTT.S253772"},{"key":"2026070211005179448_j_raon-2026-0033_ref_012","doi-asserted-by":"crossref","unstructured":"Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-9. doi: 10.1038\/nm1622","DOI":"10.1038\/nm1622"},{"key":"2026070211005179448_j_raon-2026-0033_ref_013","doi-asserted-by":"crossref","unstructured":"Chung HW, Lim JB, Jang S, Lee KJ, Park KH, Song SY. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Cancer Sci 2012; 103: 1714-21. doi: 10.1111\/j.1349-7006.2012.02358.x","DOI":"10.1111\/j.1349-7006.2012.02358.x"},{"key":"2026070211005179448_j_raon-2026-0033_ref_014","doi-asserted-by":"crossref","unstructured":"Qiu G, Li Y, Liu Z, Wang M, Ge J, Bai X. Clinical value of serum HMGB1 in diagnosis and prognosis of laryngeal squamous cell carcinoma. Med Oncol 2014; 31: 316. doi: 10.1007\/s12032-014-0316-x","DOI":"10.1007\/s12032-014-0316-x"},{"key":"2026070211005179448_j_raon-2026-0033_ref_015","doi-asserted-by":"crossref","unstructured":"Tabata C, Shibata E, Tabata R, Kanemura S, Mikami K, Nogi Y, et al. Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. BMC Cancer 2013; 13: 205. doi: 10.1186\/1471-2407-13-205","DOI":"10.1186\/1471-2407-13-205"},{"key":"2026070211005179448_j_raon-2026-0033_ref_016","doi-asserted-by":"crossref","unstructured":"Holz A, Paul B, Zapf A, Pantel K, Joosse SA. Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: a systematic review and meta-analysis. Cancer Treat Rev 2025; 139: 102999. doi: 10.1016\/j.ctrv.2025.102999","DOI":"10.1016\/j.ctrv.2025.102999"},{"key":"2026070211005179448_j_raon-2026-0033_ref_017","doi-asserted-by":"crossref","unstructured":"Bartolomucci A, Nobrega M, Ferrier T, Dickinson K, Kaorey N, Nadeau A, et al. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. NPJ Precis Oncol 2025; 9: 84. doi: 10.1038\/s41698-025-00876-y","DOI":"10.1038\/s41698-025-00876-y"},{"key":"2026070211005179448_j_raon-2026-0033_ref_018","doi-asserted-by":"crossref","unstructured":"Henriksen TV, Demuth C, Frydendahl A, Nors J, Nesic M, Rasmussen MH, et al. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort. Ann Oncol 2024; 35: 229-39. doi: 10.1016\/j.annonc.2023.11.009","DOI":"10.1016\/j.annonc.2023.11.009"},{"key":"2026070211005179448_j_raon-2026-0033_ref_019","doi-asserted-by":"crossref","unstructured":"Clasen K, Gani C, Schuetz L, Clasen S, Ballin N, Bonzheim I, et al. Dynamics of cell-free tumor DNA correlate with early MRI response during chemoradiotherapy in rectal cancer. Radiat Oncol 2024; 19: 153. doi: 10.1186\/s13014-024-02540-4","DOI":"10.1186\/s13014-024-02540-4"},{"key":"2026070211005179448_j_raon-2026-0033_ref_020","doi-asserted-by":"crossref","unstructured":"Clasen K, Ballin N, Schutz L, Bonzheim I, Kelemen O, Orth M, et al. Tumor sequencing before and after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: Genetic tumor characterization and clinical outcome. Clin Transl Radiat Oncol 2025; 50: 100894. doi: 10.1016\/j.ctro.2024.100894","DOI":"10.1016\/j.ctro.2024.100894"},{"key":"2026070211005179448_j_raon-2026-0033_ref_021","doi-asserted-by":"crossref","unstructured":"Clasen K, Welz S, Faltin H, Zips D, Eckert F. Dynamics of HMBG1 (High Mobility Group Box 1) during radiochemotherapy correlate with outcome of HNSCC patients. Strahlenther Onkol 2022; 198: 194-200. doi: 10.1007\/s00066-021-01860-8","DOI":"10.1007\/s00066-021-01860-8"},{"key":"2026070211005179448_j_raon-2026-0033_ref_022","doi-asserted-by":"crossref","unstructured":"Suzuki Y, Mimura K, Yoshimoto Y, Watanabe M, Ohkubo Y, Izawa S, et al. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 2012; 72: 3967-76. doi: 10.1158\/0008-5472.CAN-12-0851","DOI":"10.1158\/0008-5472.CAN-12-0851"},{"key":"2026070211005179448_j_raon-2026-0033_ref_023","doi-asserted-by":"crossref","unstructured":"Zandarashvili L, Sahu D, Lee K, Lee YS, Singh P, Rajarathnam K, et al. Realtime kinetics of high-mobility group box 1 (HMGB1) oxidation in extracellular fluids studied by in situ protein NMR spectroscopy. J Biol Chem 2013; 288: 11621-7. doi: 10.1074\/jbc.M113.449942","DOI":"10.1074\/jbc.M113.449942"},{"key":"2026070211005179448_j_raon-2026-0033_ref_024","doi-asserted-by":"crossref","unstructured":"Chung HW, Lee SG, Kim H, Hong DJ, Chung JB, Stroncek D, et al. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 2009; 7: 38. doi: 10.1186\/1479-5876-7-38","DOI":"10.1186\/1479-5876-7-38"},{"key":"2026070211005179448_j_raon-2026-0033_ref_025","doi-asserted-by":"crossref","unstructured":"Liikanen I, Koski A, Merisalo-Soikkeli M, Hemminki O, Oksanen M, Kairemo K, et al. Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy. Oncoimmunology 2015; 4: e989771. doi: 10.4161\/2162402X.2014.989771","DOI":"10.4161\/2162402X.2014.989771"},{"key":"2026070211005179448_j_raon-2026-0033_ref_026","doi-asserted-by":"crossref","unstructured":"Masuda K, Ono A, Aikata H, Kawaoka T, Nelson Hayes C, Teraoka Y, et al. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy. J Gastroenterol 2018; 53: 107-18. doi: 10.1007\/s00535-017-1348-8","DOI":"10.1007\/s00535-017-1348-8"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2026-0033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:03:17Z","timestamp":1782990197000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2026-0033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,26]]},"published-print":{"date-parts":[[2026,6,1]]}},"alternative-id":["10.2478\/raon-2026-0033"],"URL":"https:\/\/doi.org\/10.2478\/raon-2026-0033","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}